Table 1.
Characteristics of individuals with positive SARS-CoV-2 test following booster vaccination during Delta and Omicron periods.
| Delta period (n = 309) | Omicron period (n = 8,260) | |
|---|---|---|
| Age, years, median (IQR) | 72 (66, 77) | 69 (59, 74) |
| Sex, n(%) | ||
| Male | 286 (93) | 7,511 (9 1) |
| Female | 23 (7) | 749 (9) |
| Race/ethnicity, n(%) | ||
| Non-Hispanic white | 208 (67) | 4,663 (56) |
| Non-Hispanic black | 45 (15) | 2,194 (27) |
| Hispanic any race | 17 (5) | 432 (5) |
| Other/ unknown | 39 (13) | 971 (12) |
| Rurality, n(%) | ||
| Rural | 96 (31) | 1,922 (2 3 ) |
| Urban | 210 (68) | 6,298(76) |
| Missing | 3 (<1) | 40 (<1) |
| Booster manufacturer, n(%) | ||
| Pfizer | 163 (53) | 4,152 (50) |
| Moderna | 146 (47) | 4,108 (50) |
| 2-dose primary series manufacturer, n(%) | ||
| Pfizer | 167 (54) | 4,122 (50) |
| Moderna | 142 (46) | 4,138 (50) |
| Comorbidities1, n(%) | ||
| Asthma | 55 (18) | 1,433 (17) |
| Cancer | 47 (15) | 982 (12) |
| Chronic kidney disease | 51 (16) | 1,123 (14) |
| COPD | 56 (18) | 1,539 (19) |
| Cardiovascular disease | 34 (11) | 583 (7) |
| Diabetes, with complications | 68 (22) | 1,431 (17) |
| Diabetes, without complications | 129 (42) | 3,021 (37) |
| Hypertension | 213 (69) | 5,361 (65) |
| Immunocompromised | 97 (31) | 2,141 (26) |
| Obesity | 60 (19) | 1,556 (19) |